Status:
COMPLETED
Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures
Lead Sponsor:
UCB Pharma SA
Collaborating Sponsors:
UCB Japan Co. Ltd.
Conditions:
Epilepsy
Partial-onset Seizures
Eligibility:
All Genders
16-70 years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to evaluate the safety and tolerability of long-term administration of Lacosamide at doses up to 400 mg/day in Japanese and Chinese adults with Epilepsy who have completed...
Eligibility Criteria
Inclusion
- Subject has completed the Treatment and Transition Period of EP0008 \[NCT01710657\]
Exclusion
- Subjects who withdrew from EP0008 \[NCT01710657\]
Key Trial Info
Start Date :
March 26 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2019
Estimated Enrollment :
473 Patients enrolled
Trial Details
Trial ID
NCT01832038
Start Date
March 26 2013
End Date
July 31 2019
Last Update
August 17 2021
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
86026
Beijing, China
2
86027
Beijing, China
3
86015
Changchun, China
4
86005
Chengdu, China